AUROBINDO PHARMA
|
The Current P/E Ratio of AUROBINDO PHARMA is 20.21.
Share Price | ₹1,217.9 | Apr 25,2025 |
Market Cap | ₹70,732.7 Cr | |
Earnings-TTM | ₹3,500.3 Cr | TTM-Consolidated Results |
Price/Earnings | 20.21x | Calculated as Market Cap/Earnings |
---|---|---|
Explore Stock Analytics |
Definition & Calculation of PE (Price/Earnings) ratio of AUROBINDO PHARMA
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹70,732.7 Cr] as on Apr 25,2025
(/) Earnings [ ₹3,500.3 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 20.21x ]
Thus, for AUROBINDO PHARMA , the investors are currently willing to pay 20.21 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of AUROBINDO PHARMA !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of AUROBINDO PHARMA over the last five years.
Historical PE (Price/Earnings) ratio chart of AUROBINDO PHARMA
PE Ratio Performance Analysis for AUROBINDO PHARMA
- AUROBINDO PHARMA 's p/e ratio for fiscal years ending Mar2024 to Mar2020 averaged 13.77x.
- AUROBINDO PHARMA 's operated at median p/e ratio of 14.8x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, AUROBINDO PHARMA 's p/e ratio peaked in Mar2024 at 20.12x.
- AUROBINDO PHARMA 's p/e ratio hit its five-year low in Mar2020 of 8.51x.
How does AUROBINDO PHARMA 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
---|---|---|---|
AUROBINDO PHARMA | 3,500.25 | 20.21 | 70,732.7 |
SUN PHARMACEUTICAL INDUSTRIES LTD | 11,486.00 | 37.33 | 428,725.0 |
DIVIS LABORATORIES LTD | 2,067.00 | 77.18 | 159,525.0 |
CIPLA LTD | 5,000.43 | 24.64 | 123,206.0 |
TORRENT PHARMACEUTICALS LTD | 1,862.00 | 58.82 | 109,519.0 |
DR REDDYS LABORATORIES LTD | 5,428.60 | 18.04 | 97,927.5 |
MANKIND PHARMA LTD | 2,050.73 | 51.34 | 105,276.0 |
ZYDUS LIFESCIENCES LTD | 4,591.80 | 18.83 | 86,445.6 |
LUPIN LTD | 2,892.10 | 31.86 | 92,150.8 |
ABBOTT INDIA LTD | 1,334.46 | 47.37 | 63,212.2 |
ALKEM LABORATORIES LTD | 2,197.47 | 27.40 | 60,209.9 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs AUROBINDO PHARMA 's P/E Ratio
Top 10 Industry Peers | PE Ratio |
---|---|
Min industry PE | 18.04x |
Max industry PE | 77.18x |
Median industry PE | 31.86x |
Average industry PE | 37.55x |
You may also like the below Video Courses